{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.5"},{"groupId":"OG001","value":"81.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"Percentage of participants who had no event of death 2 years after Day 1 Cycle 1 of bortezomib, doxorubicin and dexamethasone (PAD) stratified by protein expression (FGFR3).","groups":[{"description":"Participants without FGFR3 expression","id":"OG000","title":"Negative"},{"description":"Participants with FGFR3 expression","id":"OG001","title":"Positive"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat (ITT) population - All participants who were screened and received at least one dose of PAD. The OS was not imputed.","reportingStatus":"POSTED","timeFrame":"2 years after Day 1 Cycle 1 of PAD","title":"Overall Survival (OS) Stratified by Protein Expression (FGFR3)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}